SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives $68.83 Consensus Price Target from Analysts

Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTXGet Free Report) have received a consensus recommendation of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $68.83.

A number of analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a research note on Friday, May 31st. Wedbush reissued an “outperform” rating and issued a $75.00 price target (up previously from $70.00) on shares of SpringWorks Therapeutics in a report on Thursday, May 2nd.

Check Out Our Latest Research Report on SWTX

SpringWorks Therapeutics Stock Down 5.2 %

NASDAQ SWTX opened at $33.43 on Monday. The company has a 50-day simple moving average of $38.32 and a two-hundred day simple moving average of $43.35. SpringWorks Therapeutics has a 12-month low of $18.00 and a 12-month high of $53.92. The firm has a market cap of $2.48 billion, a price-to-earnings ratio of -6.50 and a beta of 0.78.

SpringWorks Therapeutics (NASDAQ:SWTXGet Free Report) last issued its earnings results on Thursday, May 2nd. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.01). The company had revenue of $21.00 million during the quarter, compared to the consensus estimate of $12.07 million. SpringWorks Therapeutics’s revenue for the quarter was up 2000.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.18) EPS. Equities analysts expect that SpringWorks Therapeutics will post -4.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SpringWorks Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in SpringWorks Therapeutics by 0.4% in the third quarter. Vanguard Group Inc. now owns 4,922,462 shares of the company’s stock worth $113,807,000 after purchasing an additional 20,651 shares during the period. SG Americas Securities LLC bought a new stake in shares of SpringWorks Therapeutics during the 4th quarter valued at $157,000. China Universal Asset Management Co. Ltd. increased its stake in shares of SpringWorks Therapeutics by 348.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,237 shares of the company’s stock worth $264,000 after acquiring an additional 5,625 shares in the last quarter. Arizona State Retirement System lifted its position in SpringWorks Therapeutics by 33.7% during the 4th quarter. Arizona State Retirement System now owns 13,088 shares of the company’s stock valued at $478,000 after acquiring an additional 3,297 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its stake in SpringWorks Therapeutics by 131.9% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 40,000 shares of the company’s stock worth $1,490,000 after acquiring an additional 22,750 shares in the last quarter.

SpringWorks Therapeutics Company Profile

(Get Free Report

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.

Featured Stories

Analyst Recommendations for SpringWorks Therapeutics (NASDAQ:SWTX)

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.